Drug Discovery
Dizal’s China-Origin Sunvozertinib Secures FDA Priority Review for EGFR Exon20ins NSCLC
If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with E...
January 08, 2025 | News
Astellas Pharma Announces NMPA Approval of Zolbetuximab in China for Advanced Gastric and GEJ Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the National Medical Products Administration (N...
January 06, 2025 | News
Everest Medicines Announces NEFECON® NRDL Implementation in China to Expand Access for IgAN Patients
Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...
January 06, 2025 | News
RenovoRx Strengthens IP Portfolio with 18 Issued and 13 Pending Patents as it Advances TAMP™ Therapy and RenovoCath Commercialization
RenovoRx Holds a Strong IP Portfolio with 18 Issued Patents and 13 Pending Patents as it Moves Forward with Commercialization and Clinical Trial Plan...
January 02, 2025 | News
Verastem Oncology’s NDA for Avutometinib-Defactinib Combo in KRAS Mutant LGSOC Accepted by FDA with Priority Review
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced that the U.S. Food a...
January 02, 2025 | News
Corcept Therapeutics Submits NDA for Relacorilant to FDA for Cushing’s Syndrome Treatment
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocr...
January 01, 2025 | News
Huadong Medicine and SynerK PharmaTech Forge Strategic Alliance to Develop siRNA Drug for Hypertension
Hangzhou Sino-US Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine"), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.00...
December 30, 2024 | News
Australia’s Telix Submits FDA Application for TLX250-CDx, a Breakthrough PET Imaging Agent for Kidney Cancer
Telix Pharmaceuticals Limited announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administrat...
December 30, 2024 | News
Exicure Signs MOU to Acquire GPCR USA and Advance Collaborative Research in Drug Development
Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...
December 30, 2024 | News
Alphamab Oncology Receives NMPA Approval for Phase I/II Trial of Groundbreaking Subcutaneous Co-Formulation JSKN033
Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co...
December 27, 2024 | News
Taiwan’s Taikang Biotech Joins Forces with Mitsubishi Gas Chemical and Taiwan Sugar Alliance to Propel SPD8 Biosimilar Globally
Taikang Biotech (6589), Mitsubishi Gas Chemical Co., Ltd. (MGC), and the Taiwan Sugar Association (4168) have entered into a strategic tripartite agreement...
December 26, 2024 | News
Axcelead Drug Discovery Partners Joins Forces with Astellas Pharma to Advance Targeted Protein Degrader Research
Axcelead Drug Discovery Partners, Inc. announced today that it has entered into a drug discovery service agreement with Astellas Pharma, Inc. (HQ: Ch...
December 26, 2024 | News
Keymed Biosciences Secures NMPA Approval for Stapokibart to Treat Chronic Rhinosinusitis with Nasal Polyposis
Keymed Biosciences Inc. announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New D...
December 24, 2024 | News
Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
Antibody-Drug Conjugates (ADCs) represent a paradigm shift in oncology, offering targeted cancer treatment that minimizes collateral damage to healthy cell...
December 23, 2024 | News
Most Read
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
